Literature DB >> 23787765

Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis.

Charlotte R Grant1, Rodrigo Liberal, Beth S Holder, John Cardone, Yun Ma, Simon C Robson, Giorgina Mieli-Vergani, Diego Vergani, Maria Serena Longhi.   

Abstract

UNLABELLED: Autoimmune hepatitis (AIH) is an important cause of severe liver disease and is associated with both quantitative and qualitative regulatory T-cell (Treg) impairments. Tregs express CD39, an ectonucleotidase responsible for extracellular nucleotide hydrolysis, culminating in the production of immunosuppressive adenosine. Here, we describe multiple CD39(pos) Treg defects that potentially contribute to the impaired immunoregulation that is characteristic of AIH. We have examined the frequency and phenotype of CD39(pos) Tregs by flow cytometry and measured their ectonucleotidase activity. The capacity of CD4(pos) CD25(high) , CD4(pos) CD25(high) CD39(pos) , and CD4(pos) CD25(high) CD39(neg) subsets to suppress both proliferation of effector T cells and interleukin (IL)-17 production was evaluated. In AIH, CD39(pos) Tregs are decreased in frequency, exhibit limited adenosine triphosphate/adenosine diphosphate hydrolysis activity, and fail to suppress IL-17 production by effector CD4 T cells. Moreover, these CD39(pos) Tregs display a more proinflammatory profile in AIH, which is characterized by elevated CD127 positivity, and a greater propensity to produce interferon-gamma or IL-17 upon challenge with proinflammatory stimuli.
CONCLUSIONS: In AIH, CD39(pos) Tregs are decreased in number, fail to adequately hydrolyze proinflammatory nucleotides and do not efficiently suppress IL-17 production by effector CD4 T cells. CD39(pos) Tregs show plasticity and are unstable upon proinflammatory challenge, suggesting that defective immunoregulation in AIH might result not only from reduced Treg number and function, but also from increased conversion of Tregs into effector cells.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23787765      PMCID: PMC6377365          DOI: 10.1002/hep.26583

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  68 in total

1.  A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation.

Authors:  Muhammed Yuksel; Yipeng Wang; Ningwen Tai; Jian Peng; Junhua Guo; Kathie Beland; Pascal Lapierre; Chella David; Fernando Alvarez; Isabelle Colle; Huiping Yan; Giorgina Mieli-Vergani; Diego Vergani; Yun Ma; Li Wen
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

2.  Distinct roles of ecto-nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) in liver regeneration and fibrosis.

Authors:  Linda Feldbrügge; Z Gordon Jiang; Eva Csizmadia; Shuji Mitsuhashi; Stephanie Tran; Eric U Yee; Sonja Rothweiler; Kahini A Vaid; Jean Sévigny; Moritz Schmelzle; Yury V Popov; Simon C Robson
Journal:  Purinergic Signal       Date:  2017-11-13       Impact factor: 3.765

3.  HIF-1α-induced xenobiotic transporters promote Th17 responses in Crohn's disease.

Authors:  Anyan Xie; René J Robles; Samiran Mukherjee; Haohai Zhang; Linda Feldbrügge; Eva Csizmadia; Yan Wu; Keiichi Enjyoji; Alan C Moss; Leo E Otterbein; Francisco J Quintana; Simon C Robson; Maria Serena Longhi
Journal:  J Autoimmun       Date:  2018-08-08       Impact factor: 7.094

4.  The induction of autoimmune hepatitis in the human leucocyte antigen-DR4 non-obese diabetic mice autoimmune hepatitis mouse model.

Authors:  M Yuksel; X Xiao; N Tai; Manakkat Vijay; E Gülden; K Beland; P Lapierre; F Alvarez; Z Hu; I Colle; Y Ma; L Wen
Journal:  Clin Exp Immunol       Date:  2016-08-23       Impact factor: 4.330

Review 5.  Adenosine signalling in diabetes mellitus--pathophysiology and therapeutic considerations.

Authors:  Luca Antonioli; Corrado Blandizzi; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

Review 6.  Autoimmune hepatitis.

Authors:  Farhad Sahebjam; John M Vierling
Journal:  Front Med       Date:  2015-03-06       Impact factor: 4.592

Review 7.  Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.

Authors:  Petros Fessas; Lucia A Possamai; James Clark; Ella Daniels; Cathrin Gudd; Benjamin H Mullish; James L Alexander; David J Pinato
Journal:  Immunology       Date:  2019-11-19       Impact factor: 7.397

Review 8.  Hepatitis mouse models: from acute-to-chronic autoimmune hepatitis.

Authors:  Muhammed Yüksel; Debby Laukens; Femke Heindryckx; Hans Van Vlierberghe; Anja Geerts; F Susan Wong; Li Wen; Isabelle Colle
Journal:  Int J Exp Pathol       Date:  2014-08-12       Impact factor: 1.925

Review 9.  Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.

Authors:  M Segovia; S Russo; M R Girotti; G A Rabinovich; M Hill
Journal:  Clin Exp Immunol       Date:  2020-05       Impact factor: 4.330

Review 10.  Cell mediators of autoimmune hepatitis and their therapeutic implications.

Authors:  Aldo J Montano-Loza; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.